A coupling method for sorting activated magnetic beads and its application

Through magnetic bead coupling technology, CD3 and CD28 antibodies are coupled to magnetic beads, and by optimizing reaction conditions, the problems of low efficiency and low purity during T cell sorting, activation and amplification are solved, achieving efficient T- Cell sorting and activation significantly improves the purity and activity of T cells.

CN117659205BActive Publication Date: 2024-12-03BEIJING T&L BIOTECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202311656536.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-12-05
Publication Date
2024-12-03
Estimated Expiration
2043-12-05

AI Technical Summary

Technical Problem

The existing magnetic bead coupling technology has problems of low efficiency and low purity in the process of T cell sorting, activation and amplification, and traditional methods are difficult to achieve rapid separation and efficient enrichment at the same time.

Method used

A magnetic bead coupling method is used to chemically couple CD3 and CD28 monoclonal antibodies to magnetic beads, and T cells are purified by magnetic separation technology to improve the purity and activation efficiency of T cells, and optimize the pH value of MES buffer. , the addition amount, antibody concentration and proportion of EDC and NHS, and optimize the coupling reaction conditions.

Benefits of technology

The sorting efficiency, activation efficiency and expansion fold of T cells are improved, and the purity and activity of T cells are significantly improved. The optimized coupling method can promote the sorting, activation and amplification of T cells more efficiently.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117659205B_ABST
    Figure CN117659205B_ABST
Patent Text Reader

Abstract

The present invention discloses a coupling method and application of sorting activated magnetic beads. The present invention provides a coupling method of magnetic beads. The present invention also provides sorting activated magnetic beads obtained according to the coupling method of magnetic beads. The present invention provides an application of sorting activated magnetic beads obtained by the coupling method of magnetic beads in the preparation of products. The present invention also provides an application of sorting activated magnetic beads obtained by the coupling method of magnetic beads in promoting T cell sorting, activation and / or amplification. The present invention also provides an application of sorting activated magnetic beads obtained by the coupling method of magnetic beads in improving the purity of T cells.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biotechnology, and relates to a coupling method and application of sorting activated magnetic beads, and specifically to CD3 / CD28. Background Art

[0002] Magnetic bead coupling technology is based on biology and consists of interdisciplinary subjects such as bioinformatics, clinical medicine, and materials science. It is mainly used in cell separation, protein and nucleic acid purification, immunoassay, etc. With the increasing maturity of magnetic bead coupling technology and the rapid development of cell therapy, it has brought broad application prospects to the field of magnetic bead coupling antibodies.

[0003] Magnetic beads can be divided into three categories according to their structures: 1. Core-shell type: The earliest structure used by magnetic beads, the polymer completely covers the magnetic particles in the core of the magnetic beads. 2. Sandwich type: The core and outer layer of the magnetic beads are polymers, and the middle layer is magnetic particles. The process difficulty is higher than that of the core-shell type. 3. Dispersion type: The magnetic particles are randomly distributed in the polymer microspheres, which is a relatively mature process.

[0004] Compared with agarose beads, magnetic beads have significant advantages as carriers of the entire immune response:

[0005] 1) Different from the sponge-like porous structure of agarose beads, the surface of magnetic beads is less rough, and the antibody only binds to the surface of the magnetic beads, which can improve the binding efficiency of the antibody and magnetic beads and reduce non-specific binding.

[0006] 2) Magnetic separation can quickly enrich the immunomagnetic beads, greatly shortening the reaction time. Since centrifugation is not required when absorbing the supernatant, the probability of losing the immunomagnetic beads can also be reduced.

[0007] 3) Nanomagnetic beads with smaller particle size are in colloidal form and can be evenly suspended in the reaction solution, increasing the contact opportunities between the immunomagnetic beads and the sample, thereby accelerating the reaction speed and improving the binding efficiency between the immunomagnetic beads and the sample.

[0008] 4) Magnetic beads have magnetic responsiveness (also known as superparamagnetism), and can be collected by applying an external magnetic field. After the magnetic field is removed, the magnetism of the magnetic beads disappears, and then they are evenly dispersed in the solution again. In addition, magnetic beads can be endowed with surface functional groups such as hydroxyl, carboxyl, thiol and amino groups through copolymerization and surface modification, which can specifically bind to the target molecule. Summary of the invention

[0009] In order to solve the technical problems existing in the prior art, the following technical solutions are provided:

[0010] The present invention provides a magnetic bead coupling method, the coupling method comprising:

[0011] 1) Mix the magnetic beads thoroughly, add MES buffer with different pH values ​​to resuspend, mix well, let stand on the magnetic stand, discard the supernatant, and repeat step 1) multiple times;

[0012] 2) Add MES buffer with the corresponding pH value as in step 1) to resuspend, add EDC, and mix for 1 hour;

[0013] 3) Add PBS to resuspend, mix well, let stand on a magnetic rack, discard the supernatant, and repeat step 3) multiple times;

[0014] 4) Add PBS to resuspend the magnetic beads, add NHS, and mix for 1 hour;

[0015] 5) Add PBS to resuspend, mix well, let stand on a magnetic rack, discard the supernatant, and repeat step 5) multiple times;

[0016] 6) Add PBS to resuspend the magnetic beads, add CD3 and CD28 monoclonal antibody stock solutions, mix for 2.5 hours, let stand on the magnetic rack and discard the supernatant;

[0017] 7) Add PBS to resuspend, mix well, let stand on a magnetic rack, discard the supernatant, and repeat step 7) multiple times;

[0018] 8) Add blocking buffer to resuspend the magnetic beads and mix for 1 hour;

[0019] 9) After standing on the magnetic rack, discard the supernatant;

[0020] 10) Add storage buffer to resuspend, mix well, let stand on a magnetic rack, discard the supernatant, and repeat step 10) multiple times;

[0021] 11) Add storage buffer to resuspend the magnetic beads to obtain coupled magnetic beads.

[0022] In some specific embodiments, the magnetic bead raw material has a particle size of 1-10 μm. In a specific embodiment, the magnetic bead raw material is 1 μm, 1.5 μm, 2 μm, 2.5 μm, 3 μm, 3.5 μm, 4 μm, 4.5 μm, 5 μm, 5.5 μm, 6 μm, 6.5 μm, 7 μm, 7.5 μm, 8 μm, 8.5 μm, 9 μm, 9.5 μm, and 10 μm.

[0023] The term "magnetic beads" refers to microspheres with super paramagnetic properties and small particle sizes, which can quickly aggregate in a magnetic field and can be evenly dispersed after leaving the magnetic field to facilitate magnetic separation. Secondly, they have suitable and slightly different particle sizes to ensure sufficiently strong magnetic responsiveness without sedimentation. Thirdly, they have abundant surface active groups so that they can couple with biochemical substances and achieve separation from the sample to be tested under the action of an external magnetic field. Compared with traditional separation methods, the use of magnetic beads for the separation of complex components of biochemical samples can achieve separation and enrichment at the same time, effectively improving the separation speed and enrichment efficiency, while also greatly improving the sensitivity of analytical detection.

[0024] Furthermore, the magnetic beads include amino magnetic beads, carboxyl magnetic beads, epoxy magnetic beads, thiol magnetic beads, and uncoated magnetic beads.

[0025] In certain specific embodiments, the magnetic beads are carboxyl magnetic beads.

[0026] The term "resuspending" refers to the act of intentionally placing the settled precipitate back into suspension and maintaining it in suspension when washing is performed.

[0027] The terms "CD3 antibody" and "CD3 monoclonal antibody" generally refer to an antibody that can specifically recognize a CD3 subunit (e.g., CD3 epsilon, CD3 gamma, CD3 delta, or a complex thereof). The antibody may be a monoclonal antibody that can only recognize CD3, or a multi-target antibody that can simultaneously recognize CD3 and other targets.

[0028] The terms "CD28 antibody" and "CD28 monoclonal antibody" generally refer to an antibody that can specifically recognize a CD28 subunit (e.g., CD28 epsilon, CD28 gamma, CD28 delta, or a complex thereof). The antibody may be a monoclonal antibody that can only recognize CD28, or a multi-target antibody that can simultaneously recognize CD28 and other targets.

[0029] In the present application, the terms "CD3", "CD28" refer to any natural CD3 / CD28 from any vertebrate source, including mammals, such as primates (e.g., humans), non-human primates (e.g., cynomolgus monkeys) and rodents (e.g., mice and rats). The term encompasses "full-length" and unprocessed CD3 / CD28 proteins as well as any form of protein or one or more CD3 / CD28 chains (polypeptides) (e.g., mature polypeptides) derived from processing in cells. The term also encompasses naturally occurring variants and isoforms of CD3 / CD28, such as splice variants or allelic variants.

[0030] Likewise, the terms "CD3 epsilon", "CD28 epsilon", "CD3 gamma", "CD28gamma", "CD3 delta" and / or "CD28 delta" of the present application refer to any native CD3 / CD28 from any vertebrate source, including mammals, such as primates (e.g., humans), non-human primates (e.g., cynomolgus monkeys) and rodents (e.g., mice and rats). "CD3 epsilon", "CD28 epsilon", "CD3 gamma", "CD28 gamma", "CD3delta" and / or "CD28 delta" encompass "full-length" and unprocessed "CD3 epsilon", "CD28 epsilon", "CD3 gamma", "CD28 gamma", "CD3 delta" and / or "CD28 delta" proteins, respectively, as well as any form of CD3 / CD28 chain (polypeptide) (e.g., mature polypeptide) derived from processing in cells. The term also encompasses naturally occurring variants and isoforms of the CD3 / CD28 chain, such as splice variants or allelic variants.

[0031] The term "CD28" refers to the protein cluster of differentiation 28, which is one of the proteins expressed on T cells that provides the co-stimulatory signal required for T cell activation and survival.

[0032] The term "CD3" refers to a multimeric protein complex, historically known as the T3 complex, composed of four different polypeptide chains: epsilon (ε), gamma (γ), delta (δ), and zeta (ζ), which assemble and function as three pairs of dimers (εγ, εδ, ζζ).

[0033] Furthermore, in step 1) of the coupling method, the pH value ranges from 4.5 to 6.5.

[0034] In some specific embodiments, the pH value of the MES buffer is 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5. In a preferred embodiment, the pH value of the MES buffer is 5.5-6.0.

[0035] Furthermore, in the step 1), the ratio of the MES buffer used for resuspension to the added magnetic beads is 1 mL:100 μL.

[0036] Furthermore, in the step 1), after adding the MES buffer, the mixing method is to mix by turning the mixture upside down.

[0037] Furthermore, the ratio of MES buffer in step 2) to the magnetic beads added in step 1) is 300 μL:100 μL.

[0038] Furthermore, the ratio of EDC in step 2) to the magnetic beads added in step 1) is 10-50 μL:100 μL.

[0039] In some specific embodiments, the ratio of EDC to the magnetic beads in step 1) is 10 μL:100 μL, 20 μL:100 μL, 30 μL:100 μL, 40 μL:100 μL, 50 μL:100 μL. In a specific embodiment, the ratio of EDC to the magnetic beads in step 1) is 30 μL:100 μL.

[0040] Furthermore, the mixing method in step 2) is shaking mixing at room temperature.

[0041] Furthermore, the ratio of PBS in step 3) to the magnetic beads added in step 1) is 1 mL:100 μL.

[0042] Furthermore, the mixing method in step 3) is mixing by turning the mixture upside down.

[0043] Furthermore, in the step 4), the ratio of PBS to the magnetic beads added in the step 1) is 300 μL:100 μL.

[0044] Furthermore, the ratio of NHS in step 4) to the magnetic beads added in step 1) is 10-100 μL:100 μL.

[0045] In certain specific embodiments, the ratio of NHS to the magnetic beads in step 1) is 10 μL: 100 μL, 20 μL: 100 μL, 30 μL: 100 μL, 40 μL: 100 μL, 50 μL: 100 μL, 60 μL: 100 μL, 70 μL: 100 μL, 80 μL: 100 μL, 90 μL: 100 μL, 100 μL: 100 μL. In certain preferred embodiments, the ratio of NHS to the magnetic beads in step 1) is 30-100 μL: 100 μL, and in a more preferred embodiment, the ratio of NHS to the magnetic beads in step 1) is 30 μL: 100 μL.

[0046] Furthermore, the mixing method in step 4) is shaking mixing at room temperature.

[0047] Furthermore, in the step 5), the ratio of PBS to the magnetic beads added in the step 1) is 1 mL:100 μL.

[0048] Furthermore, the mixing method in step 5) is mixing by turning the mixture upside down.

[0049] Furthermore, in step 6), the ratio of PBS to the magnetic beads added in step 1) is 600 μL:100 μL.

[0050] Furthermore, in step 6), the ratio of CD3 and CD28 to the magnetic beads added in step 1) is 200-300 μL: 200-100 μL: 100 μL.

[0051] In certain specific embodiments, the ratio of CD3 to CD28 is 1-3:1, specifically including 1:1, 2:1, 3:1. In a preferred embodiment, the ratio of CD3 to CD28 is 1:1.

[0052] Furthermore, in step 6), the concentration of CD3 is 1-5 mg / mL.

[0053] Furthermore, in step 6), the concentration of CD28 is 1-5 mg / mL.

[0054] In certain specific embodiments, the concentration of CD3 is 1 mg / mL, 2 mg / mL, 3 mg / mL, 4 mg / mL, 5 mg / mL. In a specific embodiment, the concentration of CD3 is 3 mg / mL.

[0055] In certain specific embodiments, the concentration of CD28 is 1 mg / mL, 2 mg / mL, 3 mg / mL, 4 mg / mL, 5 mg / mL. In a specific embodiment, the concentration of CD28 is 3 mg / mL.

[0056] Furthermore, the mixing method in step 6) is shaking mixing at 2-8°C.

[0057] Furthermore, in step 7), the ratio of PBS to the magnetic beads added in step 1) is 1 mL:100 μL.

[0058] Furthermore, the mixing method in step 7) is mixing by turning the mixture upside down.

[0059] Furthermore, the ratio of the blocking buffer in step 8) to the magnetic beads added in step 1) is 1 mL:100 μL.

[0060] Furthermore, the mixing method in step 8) is shaking mixing at 2-8°C.

[0061] Furthermore, the ratio of the storage buffer in step 10) to the magnetic beads added in step 1) is 1 mL:100 μL.

[0062] Furthermore, the mixing method in step 10) is mixing by turning the mixture upside down.

[0063] Furthermore, the ratio of the storage buffer in step 11) to the magnetic beads added in step 1) is 200 μL:200 μL.

[0064] Furthermore, the MES buffer composition is MES: water for injection = 1.59 g: 50 mL, and the pH value is adjusted to 4.5-6.5.

[0065] Furthermore, the PBS components are NaCl: KCl: Na2HPO4: KH2PO4: water for injection = 8g: 0.2g: 1.44g: 0.24g: 1L.

[0066] Furthermore, in the step 2), the concentration of EDC is 1 mg / mL, and the components of 1 mg / mL EDC are EDC:MES=0.01 g:10 mL. The EDC needs to be prepared before use.

[0067] Furthermore, in the step 4), the concentration of NHS is 1 mg / mL, and the components of the 1 mg / mL NHS are NHS: PBS = 0.01 g: 10 mL, and the NHS needs to be prepared before use.

[0068] Furthermore, the blocking buffer comprises 20 mM PBS and 1% BSA.

[0069] Furthermore, the storage buffer comprises 20 mM PBS and 5% BSA.

[0070] The terms "particle diameter", "particle size" refer to the average diameter of the particle image, which is observed by an electron microscope or an optical microscope. Unless otherwise indicated, the term "particle diameter" is used in this manner. Unless otherwise indicated, the term "average particle diameter" means the average particle size of a collection of particles (for particles having an average particle size of at least 500 nm), or the specific surface area (in m) of particles measured using a Brunauer-Emmett-Teller method (BET method) consistent with fully dense particles (for particles having an average particle size of less than 500 nm) using a spherical model. 2 / g measurement) for calculation.

[0071] The present invention provides sorting activated magnetic beads obtained according to the above-mentioned magnetic bead coupling method.

[0072] The present invention provides an application of sorting activated magnetic beads obtained according to the magnetic bead coupling method described above in preparing products.

[0073] Furthermore, the products include reagents, test kits, and chromatography test strips.

[0074] The present invention provides an application of sorting and activation magnetic beads obtained according to the magnetic bead coupling method described above in promoting T cell sorting, activation and / or amplification.

[0075] The present invention provides an application of sorting activated magnetic beads obtained according to the magnetic bead coupling method described above in improving the purity of T cells.

[0076] In the present application, the term "antibody" generally refers to a polypeptide molecule that can specifically recognize and / or neutralize a specific antigen. For example, an antibody may comprise an immunoglobulin consisting of at least two heavy (H) chains and two light (L) chains interconnected by disulfide bonds, and includes any molecule comprising an antigen-binding portion thereof. The term "antibody" includes monoclonal antibodies, antibody fragments or antibody derivatives, including but not limited to human antibodies, humanized antibodies, chimeric antibodies, single domain antibodies (e.g., dAb), single chain antibodies (e.g., scFv), and antibody fragments that bind to antigens (e.g., Fab, Fab' and (Fab)2 fragments). The term "antibody" also includes all recombinant forms of antibodies, such as antibodies expressed in prokaryotic cells, unglycosylated antibodies, and any antibody fragments and derivatives thereof that bind to antigens described in the present application. Each heavy chain may be composed of a heavy chain variable region (VH) and a heavy chain constant region. Each light chain may be composed of a light chain variable region (VL) and a light chain constant region. The VH and VL regions can be further divided into hypervariable regions called complementarity determining regions (CDRs), which are interspersed in more conserved regions called framework regions (FRs). Each VH and VL can be composed of three CDRs and four FR regions, which can be arranged in the following order from amino terminus to carboxyl terminus: FR1, CDR1, FR2, CDR2, FR3, CDR3 and FR4. The variable regions of the heavy and light chains contain binding domains that interact with antigens.

[0077] The term "monoclonal antibody" refers to an identical antibody obtained from a population of substantially homogeneous antibodies, i.e., each antibody comprising the population excludes possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific and are induced against a single antigenic site.

[0078] In the present application, the term "and / or" should be understood to mean either one of the alternatives or both of the alternatives.

[0079] In this application, the term "comprising" generally means including the features specifically stated, but not excluding other elements.

[0080] In this application, the term "about" generally refers to a variation within a range of 0.5%-10% above or below a specified value, for example, 0.5%, 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, 5%, 5.5%, 6%, 6.5%, 7%, 7.5%, 8%, 8.5%, 9%, 9.5%, or 10% above or below a specified value. BRIEF DESCRIPTION OF THE DRAWINGS

[0081] Figure 1 This is the sorting efficiency diagram of the magnetic beads obtained by the method of Example 1

[0082] Figure 2 is a diagram of the activation efficiency of the magnetic beads obtained by the method of Example 1;

[0083] Figure 3 This is a graph of the amplification fold of the magnetic beads obtained by the method of Example 1;

[0084] Figure 4 is a diagram of the sorting efficiency of magnetic beads obtained by the method of Example 2;

[0085] Figure 5 is a diagram of the activation efficiency of the magnetic beads obtained by the method of Example 2;

[0086] Figure 6 This is a graph of the amplification fold of the magnetic beads obtained by the method of Example 2;

[0087] Figure 7 is a diagram of the sorting efficiency of magnetic beads obtained by the method of Example 3;

[0088] Figure 8 is a diagram of the activation efficiency of the magnetic beads obtained by the method of Example 3;

[0089] Fig. 9 This is a graph of the amplification fold of the magnetic beads obtained by the method of Example 3;

[0090] Fig.10 is a diagram of the sorting efficiency of magnetic beads obtained by the method of Example 4;

[0091] Fig.11 is a diagram of the activation efficiency of the magnetic beads obtained by the method of Example 4;

[0092] Fig.12 is a graph of the amplification fold of the magnetic beads obtained by the method of Example 4;

[0093] Fig.13 is a diagram of the sorting efficiency of magnetic beads obtained by the method of Example 5;

[0094] Fig.14 is a diagram of the activation efficiency of the magnetic beads obtained by the method of Example 5;

[0095] Fig.15 This is a graph of the amplification multiples of the magnetic beads obtained by the method of Example 5;

[0096] Fig.16 is a diagram of the sorting efficiency of magnetic beads obtained by the method of Example 6;

[0097] Fig.17 is a diagram of the activation efficiency of the magnetic beads obtained by the method of Example 6;

[0098] Fig.18 This is a graph of the amplification multiples of the magnetic beads obtained by the method of Example 6. DETAILED DESCRIPTION

[0099] Unless otherwise limited, all technical and scientific terms used herein have the same meaning as those of ordinary skill in the art to which the present invention belongs. All publications, patent applications, patents and other references mentioned herein are incorporated by reference in their entirety. In addition, the materials, methods and examples described herein are only illustrative and are not intended to be restrictive. Other features, purposes and advantages of the present invention will be apparent from this specification and the accompanying drawings and from the appended claims.

[0100] In order to solve the problem of T cell sorting, activation and amplification, the present invention chemically couples CD3 and CD28 antibodies to magnetic beads by magnetic bead-coupled antibody technology. By CD3 / CD28 immunomagnetic beads (hereinafter referred to as immunomagnetic beads) and cell co-incubation, immunomagnetic beads specifically bind to T cells, and T cells are separated and purified by magnetic separation technology to improve T cell purity. Immunomagnetic beads have the first messenger CD3 and the second messenger CD28 that activate T cells, and T cells can be quickly activated to promote the amplification of T cells.

[0101] Example 1

[0102] 1. Experimental Materials

[0103] Carboxyl magnetic beads (naked beads), MES buffer, CB buffer, blocking buffer, storage buffer, anti-human CD3 monoclonal antibody, anti-human CD28 monoclonal antibody, EDC, NHS,

[0104] 2. Reagent preparation

[0105] 1) MES buffer (molecular weight: 213.25): weigh 1.59 g of MES, dissolve it in 50 mL of water for injection, and adjust the pH value to pH 4.5-6.5 with NaOH.

[0106] 2) 1 mg / mL EDC: 0.01 g EDC dry powder is dissolved in 10 mL of 0.15 M MES (prepared on the spot).

[0107] 3) 1 mg / mL NHS: 0.01 g NHS dry powder is dissolved in 10 mL of 20 mM PBS (prepared before use).

[0108] 4) PBS: NaCl 8g, KCl 0.2g, Na2HPO4 1.44g, KH2PO4 0.24g, dissolved in 1L water for injection.

[0109] 5) Blocking solution: 20 mM PBS + 1% BSA.

[0110] 6) Storage solution: 20mM PBS+5‰ BSA.

[0111] 3. Experimental methods

[0112] (1) Magnetic bead coupling

[0113] 1) Take out the carboxyl magnetic beads from the refrigerator at 2-8°C and mix thoroughly on a vortex shaker for 1 min.

[0114] 2) Place the carboxyl magnetic beads in a biosafety cabinet, mix thoroughly by turning upside down, take out 100 μL of carboxyl magnetic beads, put them into a sterile 1.5 mL Eppendorf tube, and resuspend them in 1 mL of MES buffer with different pH values ​​according to the following experimental scheme. The details are shown in Table 1, and mix thoroughly by turning upside down.

[0115] Table 1

[0116] Group 1 Group 2 Group 3 Group 4 Group 5 MES pH 4.5 5.0 5.5 6.0 6.5

[0117] 3) Place the Eppendorf tube on the magnetic rack, let it stand for 1 min, and discard the supernatant.

[0118] 4) Remove the tube from the magnetic rack, add 1 mL of MES buffer with the corresponding pH value to resuspend, and mix by inverting.

[0119] 5) Repeat steps 3) and 4);

[0120] 6) Place the Eppendorf tube on the magnetic stand, let it stand for 1 min, discard the supernatant, aspirate as much as possible, and add 300 μL of MES buffer with the corresponding pH value to resuspend the magnetic beads.

[0121] 7) Add 30 μL of 1 mg / mL EDC and shake at room temperature for 1 h.

[0122] 8) Add 1 mL of PBS to resuspend, place the Eppendorf tube on a magnetic rack, let stand for 1 min, and discard the supernatant.

[0123] 9) Remove the tube from the magnetic rack, add 1 mL of PBS to resuspend, mix by inverting, place the Ep tube on the magnetic rack, let it stand for 1 min, and discard the supernatant.

[0124] 10) Repeat step 9) 2 times.

[0125] 11) Resuspend the magnetic beads in 300 μL PBS, add 30 μL 1 mg / mL NHS, and shake at room temperature for 1 hour.

[0126] 12) Add 1 mL PBS to resuspend, place the Eppendorf tube on a magnetic rack, let stand for 1 min, and discard the supernatant.

[0127] 13) Remove the tube from the magnetic rack, add 1 mL of PBS to resuspend, mix by inverting, place the Ep tube on the magnetic rack, let it stand for 1 min, and discard the supernatant.

[0128] 14) Repeat step 13) twice and add 1 mL PBS to resuspend the magnetic beads.

[0129] 15) Remove the Eppendorf tube from the magnetic stand, add 600 μL PBS to resuspend the magnetic beads, and then add 200 μL of 1 mg / mL CD3 and CD28 monoclonal antibody stock solutions.

[0130] 16) Mix by inverting and shaking at 2-8℃ for 2.5h.

[0131] 17) Place the Eppendorf tube on the magnetic rack, let it stand for 1 minute and discard the supernatant.

[0132] 18) Remove the tube from the magnetic stand, add 1 mL of PBS to resuspend, and invert to mix.

[0133] 19) Repeat steps 17) and 18);

[0134] 20) Place the Eppendorf tube on the magnetic rack, let it stand for 1 minute, discard the supernatant, aspirate as much as possible, and resuspend the magnetic beads in 1 mL of blocking buffer.

[0135] 21) Mix by shaking at 2-8℃ for 1 hour.

[0136] 22) Place the Eppendorf tube on the magnetic rack, let it stand for 1 min, and discard the supernatant.

[0137] 23) Remove the tube from the magnetic rack, add 1 mL of storage buffer to resuspend, and invert to mix.

[0138] 24) Repeat steps 22) and 23) twice;

[0139] 25) Place the Eppendorf tube on the magnetic rack, let it stand for 1 minute, discard the supernatant, aspirate as much as possible, and resuspend the magnetic beads in 200 μL storage buffer.

[0140] 26) If you do not proceed to the next step, wrap the tube with sealing film and store it at 4℃.

[0141] (2) Magnetic bead activity test

[0142] 1) Human PBMC cells were resuspended in PBS buffer containing 1% HSA, and samples were taken for counting and CD3 labeling for flow cytometry detection.

[0143] 2) According to the CD3 positive rate of PBMC cells, the CD3+ T cell density was adjusted to 1×10 7 cells / mL.

[0144] 3) Resuspend the magnetic beads (vortex for at least 30 seconds, or invert and mix for 5 minutes).

[0145] 4) Transfer the beads to a centrifuge tube in a 1:1 ratio between the number of magnetic beads and the CD3+T cells.

[0146] 5) Add 1 mL of PBS buffer containing 1% HSA to the above centrifuge tube, resuspend the magnetic beads, and rinse them by pipetting or vortexing.

[0147] 6) Place the centrifuge tube containing the resuspended magnetic beads on a magnetic stand (special for magnetic beads), let it stand for 1 minute, discard the supernatant, and be careful not to absorb the magnetic beads.

[0148] 7) Add PBMCs with adjusted CD3+ T cell density to the washed magnetic beads according to the proportion and mix well.

[0149] 8) Place the above centrifuge tube on a sample mixer at a speed of 15-30 rpm and incubate at room temperature for 30 minutes.

[0150] 9) Place the above centrifuge tube on a magnetic stand (special for magnetic beads), let it stand for 1 minute, collect the supernatant and perform counting and flow cytometry, and mark CD3.

[0151] 10) Resuspend the mixture of magnetic beads and cells in complete medium containing 200 IU / mL rh IL-2 and adjust the cell density to 1×10 6 cells / mL.

[0152] 11) The cell suspension was placed in a cell culture container and cultured in a 37° C., 5% CO 2 incubator for 48 hours. Samples were taken to remove the magnetic beads, and then counted and the activation efficiency (CD69+CD25+ percentage) was tested.

[0153] 12) Observe the cell status and replenish fluid regularly. When the cell density exceeds 2.5×10 6 When the culture medium turns yellow, adjust the cell density to 1×10 6 cells / mL. The cells can be harvested after culturing for 14 days.

[0154] 4. Experimental results

[0155] 1) Sorting efficiency

[0156] like Figure 1 As shown in Table 2, as the pH value of the MES solution gradually increases, the sorting efficiency is highest when the MES pH value is 6.0, indicating that the optimal pH value for the reaction between EDC and the carboxyl groups on the magnetic beads is 6.0. The specific sorting efficiency of each group is shown in Table 2.

[0157] Table 2 Sorting efficiency

[0158] Group 1 Group 2 Group 3 Group 4 Group 5 20.54 40.82 85.08 98.22 90.31 30.58 48.93 90.58 94.54 85.37

[0159] 2) Activation efficiency

[0160] like Figure 2 As shown in Table 3, there is no significant difference in activation efficiency between groups 1 and 5, indicating that the pH value of MES has no effect on the activation efficiency.

[0161] Table 3 Activation efficiency

[0162] Group 1 Group 2 Group 3 Group 4 Group 5 80.2 79.1 82.6 81.7 82.5 84.39 82.54 88.49 83.49 87.43

[0163] 3) Amplification multiple

[0164] like Figure 3 As shown in Table 4, the amplification times of Group 3 and Group 4 were higher than those of other groups, indicating that the amplification times were acceptable when the pH value of MES was between 5.5 and 6.0. The specific amplification times are shown in Table 4.

[0165] Table 4 Amplification times

[0166]

[0167] In summary, Example 1 optimizes the reaction between EDC and the carboxyl group on the magnetic beads by different pH values ​​of MES, and analyzes the three indicators of sorting efficiency, activation efficiency, and amplification multiple. When comparing the experimental data, it is found that when the pH value of MES is 6.0, the data of various indicators are better. Therefore, it can be concluded that when the pH value of MES is 6.0, it is the optimal condition for this experiment.

[0168] Example 2

[0169] 1. Experimental Materials

[0170] Carboxyl magnetic beads (naked beads), MES buffer, CB buffer, blocking buffer, storage buffer, anti-human CD3 monoclonal antibody, anti-human CD28 monoclonal antibody, EDC, NHS,

[0171] 2. Reagent preparation

[0172] The reagents were prepared in the same manner as in Example 1.

[0173] 3. Experimental methods

[0174] (1) Magnetic bead coupling

[0175] 1) Take out the carboxyl magnetic beads from the 2-8°C refrigerator according to the experimental protocol and mix thoroughly on a vortex shaker for 1 min.

[0176] 2) Place the carboxyl magnetic beads in a biosafety cabinet, mix thoroughly by turning upside down, take out 100 μL of carboxyl magnetic beads, put them into a sterile 1.5 mL Eppendorf tube, add 1 mL of MES buffer to resuspend, and mix thoroughly by turning upside down.

[0177] 3) Place the Eppendorf tube on the magnetic rack, let it stand for 1 min, and discard the supernatant.

[0178] 4) Remove the tube from the magnetic rack, add 1 mL of MES buffer to resuspend, and mix by inverting.

[0179] 5) Repeat steps 3) and 4);

[0180] 6) Place the Eppendorf tube on the magnetic rack, let it stand for 1 min, discard the supernatant, aspirate as much as possible, and resuspend the magnetic beads in 300 μL MES buffer.

[0181] 7) According to the experimental scheme described in Table 5, different volumes of EDC were added and mixed by shaking at room temperature for 1 h.

[0182] Table 5

[0183] Group 1 Group 2 Group 3 Group 4 EDC addition amount 10μL 30μL 50μL 100μL

[0184] 8) Add 1 mL of PBS to resuspend, place the Eppendorf tube on a magnetic rack, let stand for 1 min, and discard the supernatant.

[0185] 9) Remove the tube from the magnetic rack, add 1 mL of PBS to resuspend, mix by inverting, place the Ep tube on the magnetic rack, let it stand for 1 min, and discard the supernatant.

[0186] 10) Repeat step 9) 2 times.

[0187] 11) Resuspend the magnetic beads in 300 μL PBS, add 30 μL 1 mg / mL NHS, and shake at room temperature for 1 hour.

[0188] 12) Add 1 mL PBS to resuspend, place the Eppendorf tube on a magnetic rack, let stand for 1 min, and discard the supernatant.

[0189] 13) Remove the tube from the magnetic rack, add 1 mL of PBS to resuspend, mix by inverting, place the Ep tube on the magnetic rack, let it stand for 1 min, and discard the supernatant.

[0190] 14) Repeat step 13) twice and add 1 mL PBS to resuspend the magnetic beads.

[0191] 15) Remove the Eppendorf tube from the magnetic stand, add 600 μL PBS to resuspend the magnetic beads, and then add 200 μL of 1 mg / mL CD3 and CD28 monoclonal antibody stock solutions.

[0192] 16) Mix by inverting and shaking at 2-8℃ for 2.5h.

[0193] 17) Place the Eppendorf tube on the magnetic rack, let it stand for 1 minute and discard the supernatant.

[0194] 18) Remove the tube from the magnetic stand, add 1 mL of PBS to resuspend, and invert to mix.

[0195] 19) Repeat steps 17) and 18);

[0196] 20) Place the Eppendorf tube on the magnetic rack, let it stand for 1 minute, discard the supernatant, aspirate as much as possible, and resuspend the magnetic beads in 1 mL of blocking buffer.

[0197] 21) Mix by shaking at 2-8℃ for 1 hour.

[0198] 22) Place the Eppendorf tube on the magnetic rack, let it stand for 1 min, and discard the supernatant.

[0199] 23) Remove the tube from the magnetic rack, add 1 mL of storage buffer to resuspend, and invert to mix.

[0200] 24) Repeat steps 22) and 23) twice;

[0201] 25) Place the Eppendorf tube on the magnetic rack, let it stand for 1 minute, discard the supernatant, aspirate as much as possible, and resuspend the magnetic beads in 200 μL storage buffer.

[0202] 26) If you do not proceed to the next step, wrap the tube with sealing film and store it at 4℃.

[0203] (2) Magnetic bead activity test

[0204] The steps are the same as those of the magnetic bead activity test in Example 1.

[0205] 4. Experimental results

[0206] 1) Sorting efficiency

[0207] like Figure 4 As shown in Table 6, as the amount of EDC added gradually increases, the sorting efficiency gradually increases. The specific sorting efficiency of each group is shown in Table 6.

[0208] Table 6 Sorting efficiency

[0209] Group 1 Group 2 Group 3 Group 4 33.3 45.71 54.15 60.42 31.88 51.74 56.12 63.19

[0210] 2) Activation efficiency

[0211] like Figure 5 As shown, there is no significant difference in activation efficiency between groups 1 to 3, and the activation efficiency of group 4 decreases. This indicates that the addition amount of 1 mg / mL EDC between 10 μL and 50 μL has no effect on the activation efficiency. The specific results are shown in Table 7.

[0212] Table 7 Activation efficiency

[0213] Group 1 Group 2 Group 3 Group 4 77 73.3 79.5 68.15 80.6 82.6 77.4 64.42

[0214] 3) Amplification multiple

[0215] like Figure 6 As shown in Table 8, the amplification times of Group 2 and Group 3 are higher than those of Group 1 and Group 4, indicating that the addition amount of 1 mg / mL EDC can be between 10 μL and 50 μL. The specific amplification times are shown in Table 8.

[0216] Table 8 Amplification times

[0217]

[0218] In summary, Example 2 carried out the coupling reaction of CD3 / CD28 antibody and magnetic beads by adding different amounts of EDC. The comprehensive sorting efficiency, activation efficiency, and amplification multiple experimental data showed that when 1 mg / mL EDC was added at 30 μL to 50 μL, the result was better. Combined with the cost factor, it can be concluded that when 1 mg / mL EDC was added at 30 μL, it was the optimal condition for this experiment.

[0219] Example 3

[0220] 1. Experimental Materials

[0221] Carboxyl magnetic beads (naked beads), MES buffer, CB buffer, blocking buffer, storage buffer, anti-human CD3 monoclonal antibody, anti-human CD28 monoclonal antibody, EDC, NHS,

[0222] 2. Reagent preparation

[0223] The reagents were prepared in the same manner as in Example 1.

[0224] 3. Experimental methods

[0225] 1) Take out the carboxyl magnetic beads from the 2-8°C refrigerator according to the experimental protocol and mix thoroughly on a vortex shaker for 1 min.

[0226] 2) Place the carboxyl magnetic beads in a biosafety cabinet, mix thoroughly by turning upside down, take out 100 μL of carboxyl magnetic beads, put them into a sterile 1.5 mL Eppendorf tube, add 1 mL of MES buffer to resuspend, and mix thoroughly by turning upside down.

[0227] 3) Place the Eppendorf tube on the magnetic rack, let it stand for 1 min, and discard the supernatant.

[0228] 4) Remove the tube from the magnetic rack, add 1 mL of MES buffer to resuspend, and mix by inverting.

[0229] 5) Repeat steps 3) and 4);

[0230] 6) Place the Eppendorf tube on the magnetic rack, let it stand for 1 min, discard the supernatant, aspirate as much as possible, and resuspend the magnetic beads in 300 μL MES buffer.

[0231] 7) Add 30 μL of 1 mg / mL EDC and shake at room temperature for 1 h.

[0232] 8) Add 1 mL of PBS to resuspend, place the Eppendorf tube on a magnetic rack, let stand for 1 min, and discard the supernatant.

[0233] 9) Remove the tube from the magnetic rack, add 1 mL of PBS to resuspend, mix by inverting, place the Ep tube on the magnetic rack, let it stand for 1 min, and discard the supernatant.

[0234] 10) Repeat step 9) 2 times.

[0235] 11) Resuspend the magnetic beads in 300 μL PBS, add NHS according to Table 9, and shake at room temperature for 1 hour.

[0236] Table 9

[0237] Group 1 Group 2 Group 3 Group 4 NHS addition amount 10μL 30μL 50μL 100μL

[0238] 12) Add 1 mL PBS to resuspend, place the Eppendorf tube on a magnetic rack, let stand for 1 min, and discard the supernatant.

[0239] 13) Remove the tube from the magnetic rack, add 1 mL PBS to resuspend, mix by inverting, place the Ep tube on the magnetic rack, let it stand for 1 min, and discard the supernatant.

[0240] 14) Repeat step 13) twice and add 1 mL PBS to resuspend the magnetic beads.

[0241] 15) Remove the Eppendorf tube from the magnetic stand, add 600 μL PBS to resuspend the magnetic beads, and then add 200 μL of 1 mg / mL CD3 and CD28 monoclonal antibody stock solutions.

[0242] 16) Mix by inverting and shaking at 2-8℃ for 2.5 h.

[0243] 17) Place the Eppendorf tube on the magnetic rack, let it stand for 1 min, and discard the supernatant.

[0244] 18) Remove the tube from the magnetic stand, add 1 mL PBS to resuspend, and invert to mix.

[0245] 19) Repeat steps 17) and 18);

[0246] 20) Place the Eppendorf tube on the magnetic rack, let it stand for 1 min, discard the supernatant, aspirate as much as possible, and resuspend the magnetic beads in 1 mL of blocking buffer.

[0247] 21) Mix by shaking at 2-8℃ for 1 h.

[0248] 22) Place the Eppendorf tube on the magnetic rack, let it stand for 1 min, and discard the supernatant.

[0249] 23) Remove the tube from the magnetic rack, add 1 mL of storage buffer to resuspend, and invert to mix.

[0250] 24) Repeat steps 22) and 23) twice;

[0251] 25) Place the Eppendorf tube on the magnetic rack, let it stand for 1 min, discard the supernatant, aspirate as much as possible, and resuspend the magnetic beads in 200 μL storage buffer.

[0252] 26) If you do not proceed to the next step, wrap the tube with sealing film and store it at 4℃.

[0253] (2) Magnetic bead activity test

[0254] The steps are the same as those of the magnetic bead activity test in Example 1.

[0255] 4. Experimental results

[0256] 1) Sorting efficiency

[0257] like Figure 7 As shown in Table 10, as the amount of NHS added gradually increased, the sorting efficiency gradually increased. The specific sorting efficiency of each group is shown in Table 10.

[0258] Table 10 Sorting efficiency

[0259] Group 1 Group 2 Group 3 Group 4 44.32 58.67 67.97 62.05 46.32 54.67 59.97 60.05

[0260] 2) Activation efficiency

[0261] like Figure 8As shown, there was no significant difference in activation efficiency between groups 1 to 4, indicating that the addition of 1 mg / mL NHS between 10 μL and 100 μL had no effect on the activation efficiency. The specific activation efficiency of each group is shown in Table 11.

[0262] Table 11 Activation efficiency

[0263] Group 1 Group 2 Group 3 Group 4 77.7 84.7 83.4 78.15 70.43 82.8 78.4 72.42

[0264] 3) Amplification multiple

[0265] like Fig. 9 As shown in Table 12, the amplification multiple of group 1 was low, and there was no significant difference in the amplification multiples of group 2 to group 4, indicating that the amount of 1 mg / mL NHS added can be between 30 μL and 100 μL. The specific amplification multiples of each group are shown in Table 12.

[0266] Table 12 Amplification times

[0267]

[0268] In summary, in Example 3, the coupling reaction of CD3 / CD28 antibody and magnetic beads was carried out by adding different amounts of NHS. The experimental data of sorting efficiency, activation efficiency and amplification multiple were comprehensively analyzed. It was found that when 30 μL to 100 μL of 1 mg / mL NHS was added, the result was better. Combined with the cost factor, it can be concluded that when 30 μL of 1 mg / mL NHS was added, it was the optimal condition for this experiment.

[0269] Example 4

[0270] 1. Experimental Materials

[0271] Carboxyl magnetic beads (naked beads), MES buffer, CB buffer, blocking buffer, storage buffer, anti-human CD3 monoclonal antibody, anti-human CD28 monoclonal antibody, EDC, NHS,

[0272] 2. Reagent preparation

[0273] The reagents were prepared in the same manner as in Example 1.

[0274] 3. Experimental methods

[0275] (1) Magnetic bead coupling

[0276] 1) Take out the carboxyl magnetic beads from the 2-8°C refrigerator according to the experimental protocol and mix thoroughly on a vortex shaker for 1 min.

[0277] 2) Place the carboxyl magnetic beads in a biosafety cabinet, mix thoroughly by turning upside down, take out 100 μL of carboxyl magnetic beads, put them into a sterile 1.5 mL Eppendorf tube, add 1 mL of MES buffer to resuspend, and mix thoroughly by turning upside down.

[0278] 3) Place the Eppendorf tube on the magnetic rack, let it stand for 1 min, and discard the supernatant.

[0279] 4) Remove the tube from the magnetic rack, add 1 mL of MES buffer to resuspend, and mix by inverting.

[0280] 5) Repeat steps 3) and 4);

[0281] 6) Place the Eppendorf tube on the magnetic rack, let it stand for 1 min, discard the supernatant, aspirate as much as possible, and resuspend the magnetic beads in 300 μL MES buffer.

[0282] 7) Add 30 μL of 1 mg / mL EDC and shake at room temperature for 1 h.

[0283] 8) Add 1 mL of PBS to resuspend, place the Eppendorf tube on a magnetic rack, let stand for 1 min, and discard the supernatant.

[0284] 9) Remove the tube from the magnetic rack, add 1 mL of PBS to resuspend, mix by inverting, place the Ep tube on the magnetic rack, let it stand for 1 min, and discard the supernatant.

[0285] 10) Repeat step 9) 2 times.

[0286] 11) Resuspend the magnetic beads in 300 μL PBS, add 30 μL 1 mg / mL NHS, and shake at room temperature for 1 hour.

[0287] 12) Add 1 mL PBS to resuspend, place the Eppendorf tube on a magnetic rack, let stand for 1 min, and discard the supernatant.

[0288] 13) Remove the tube from the magnetic rack, add 1 mL of PBS to resuspend, mix by inverting, place the Ep tube on the magnetic rack, let it stand for 1 min, and discard the supernatant.

[0289] 14) Repeat step 13) twice and add 1 mL PBS to resuspend the magnetic beads.

[0290] 15) Move the Eppendorf tube off the magnetic stand, add 600 μL PBS to resuspend the magnetic beads, and add different concentrations of CD3 / CD28 monoclonal antibody stock solutions according to Table 13.

[0291] Table 13

[0292] Group 1 Group 2 Group 3 Group 4 CD3 / CD28 monoclonal antibody stock concentration 0.5mg / mL 1mg / mL 3mg / mL 5mg / mL CD3 monoclonal antibody stock solution addition amount 200μL 200μL 200μL 200μL CD28 monoclonal antibody stock solution added 200μL 200μL 200μL 200μL

[0293] 16) Mix by inverting and shaking at 2-8℃ for 2.5h.

[0294] 17) Place the Eppendorf tube on the magnetic rack, let it stand for 1 minute and discard the supernatant.

[0295] 18) Remove the tube from the magnetic stand, add 1 mL of PBS to resuspend, and invert to mix.

[0296] 19) Repeat steps 17) and 18);

[0297] 20) Place the Eppendorf tube on the magnetic rack, let it stand for 1 minute, discard the supernatant, aspirate as much as possible, and resuspend the magnetic beads in 1 mL of blocking buffer.

[0298] 21) Mix by shaking at 2-8℃ for 1 hour.

[0299] 22) Place the Eppendorf tube on the magnetic rack, let it stand for 1 min, and discard the supernatant.

[0300] 23) Remove the tube from the magnetic rack, add 1 mL of storage buffer to resuspend, and invert to mix.

[0301] 24) Repeat steps 22) and 23) twice;

[0302] 25) Place the Eppendorf tube on the magnetic rack, let it stand for 1 minute, discard the supernatant, aspirate as much as possible, and resuspend the magnetic beads in 200 μL storage buffer.

[0303] 26) If you do not proceed to the next step, wrap the tube with sealing film and store it at 4℃.

[0304] (2) Magnetic bead activity test

[0305] The steps are the same as those of the magnetic bead activity test in Example 1.

[0306] 4. Experimental results

[0307] 1) Sorting efficiency

[0308] like Fig.10 As shown in Table 14, except for the poor sorting efficiency of Group 1, there was no significant difference in sorting efficiency between Groups 2 to 4, indicating that the sorting efficiency was good when the antibody concentration was between 1 and 5 mg / mL. The specific sorting efficiency is shown in Table 14.

[0309] Table 14 Sorting efficiency

[0310] Group 1 Group 2 Group 3 Group 4 42.36 53.03 62.66 66.42 32.72 58.87 57.6 68.19

[0311] 2) Activation efficiency

[0312] like Fig.11 As shown, there is no significant difference in activation efficiency between groups 1 and 4, indicating that the antibody concentration has no effect on the activation efficiency. The specific activation efficiency is shown in Table 15.

[0313] Table 15 Activation efficiency

[0314] Group 1 Group 2 Group 3 Group 4 87.28 88.07 87.3 85.17 86.76 88.09 88.44 86.42

[0315] 3) Amplification multiple

[0316] like Fig.12 As shown in Table 16, the amplification times of Groups 2 to 4 were all higher than those of Group 1, while there was no significant difference between Groups 2 to 4, indicating that the amplification times were acceptable when the antibody concentration was between 1 and 5 mg / mL. The specific amplification times are shown in Table 16.

[0317] Table 16 Amplification times

[0318]

[0319] In summary, Example 4 coupled magnetic beads with different antibody concentrations, and comprehensively analyzed the sorting efficiency, activation efficiency, and amplification multiple experimental data to find that when the concentration of CD3 and CD28 antibodies was ≥1 mg / mL, there was no significant difference in the various indicators. Combined with the antibody cost factor, it can be concluded that when the concentration of CD3 and CD28 antibodies was equal to 1 mg / mL, it was the optimal condition for this experiment.

[0320] Example 5

[0321] 1. Experimental Materials

[0322] Carboxyl magnetic beads (naked beads), MES buffer, CB buffer, blocking buffer, storage buffer, anti-human CD3 monoclonal antibody, anti-human CD28 monoclonal antibody, EDC, NHS,

[0323] 2. Reagent preparation

[0324] The reagents were prepared in the same manner as in Example 1.

[0325] 3. Experimental methods

[0326] (1) Magnetic bead coupling

[0327] 1) Take out the carboxyl magnetic beads from the 2-8°C refrigerator according to the experimental protocol and mix thoroughly on a vortex shaker for 1 min.

[0328] 2) Place the carboxyl magnetic beads in a biosafety cabinet, mix thoroughly by turning upside down, take out 100 μL of carboxyl magnetic beads, put them into a sterile 1.5 mL Eppendorf tube, add 1 mL of MES buffer to resuspend, and mix thoroughly by turning upside down.

[0329] 3) Place the Eppendorf tube on the magnetic rack, let it stand for 1 min, and discard the supernatant.

[0330] 4) Remove the tube from the magnetic rack, add 1 mL of MES buffer to resuspend, and mix by inverting.

[0331] 5) Repeat steps 3) and 4);

[0332] 6) Place the Eppendorf tube on the magnetic rack, let it stand for 1 min, discard the supernatant, aspirate as much as possible, and resuspend the magnetic beads in 300 μL MES buffer.

[0333] 7) Add 30 μL of 1 mg / mL EDC and shake at room temperature for 1 h.

[0334] 8) Add 1 mL of PBS to resuspend, place the Eppendorf tube on a magnetic rack, let stand for 1 min, and discard the supernatant.

[0335] 9) Remove the tube from the magnetic rack, add 1 mL of PBS to resuspend, mix by inverting, place the Ep tube on the magnetic rack, let it stand for 1 min, and discard the supernatant.

[0336] 10) Repeat step 9) 2 times.

[0337] 11) Resuspend the magnetic beads in 300 μL PBS, add 30 μL 1 mg / mL NHS, and shake at room temperature for 1 hour.

[0338] 12) Add 1 mL PBS to resuspend, place the Eppendorf tube on a magnetic rack, let stand for 1 min, and discard the supernatant.

[0339] 13) Remove the tube from the magnetic rack, add 1 mL of PBS to resuspend, mix by inverting, place the Ep tube on the magnetic rack, let it stand for 1 min, and discard the supernatant.

[0340] 14) Repeat step 13) twice and add 1 mL PBS to resuspend the magnetic beads.

[0341] 15) Remove the Eppendorf tube from the magnetic rack, add 600 μL PBS to resuspend the magnetic beads, and add CD3 / CD28 monoclonal antibody stock solutions in different proportions according to Table 17.

[0342] Table 17

[0343] Group 1 Group 2 Group 3 Group 4 CD3 / CD28 monoclonal antibody stock concentration 1mg / mL 1mg / mL 1mg / mL 1mg / mL CD3:CD28 monoclonal antibody stock solution addition ratio 0.5:1 1:1 2:1 3:1 CD3 monoclonal antibody stock solution addition amount 133μL 200μL 267μL 300μL CD28 monoclonal antibody stock solution added 267μL 200μL 133μL 100μL

[0344] 16) Mix by inverting and shaking at 2-8℃ for 2.5h.

[0345] 17) Place the Eppendorf tube on the magnetic rack, let it stand for 1 minute and discard the supernatant.

[0346] 18) Remove the tube from the magnetic stand, add 1 mL of PBS to resuspend, and invert to mix.

[0347] 19) Repeat steps 17) and 18);

[0348] 20) Place the Eppendorf tube on the magnetic rack, let it stand for 1 minute, discard the supernatant, aspirate as much as possible, and resuspend the magnetic beads in 1 mL of blocking buffer.

[0349] 21) Mix by shaking at 2-8℃ for 1 hour.

[0350] 22) Place the Eppendorf tube on the magnetic rack, let it stand for 1 min, and discard the supernatant.

[0351] 23) Remove the tube from the magnetic rack, add 1 mL of storage buffer to resuspend, and invert to mix.

[0352] 24) Repeat steps 22) and 23) twice;

[0353] 25) Place the Eppendorf tube on the magnetic rack, let it stand for 1 minute, discard the supernatant, aspirate as much as possible, and resuspend the magnetic beads in 200 μL storage buffer.

[0354] 26) If you do not proceed to the next step, wrap the tube with sealing film and store it at 4℃.

[0355] (2) Magnetic bead activity test

[0356] The steps are the same as those of the magnetic bead activity test in Example 1.

[0357] 4. Experimental results

[0358] 1) Sorting efficiency: Fig.13 As shown in Table 18, there is no significant difference in sorting efficiency between Groups 1 and 4, indicating that the antibody ratio does not affect the sorting efficiency.

[0359] Table 18 Sorting efficiency

[0360] Group 1 Group 2 Group 3 Group 4 42.36 53.03 62.66 66.42 32.72 58.87 57.6 68.19

[0361] 2) Activation efficiency: Fig.14 As shown, the activation efficiency of group 1 is slightly lower than that of the other three groups, and there is no significant difference in the activation efficiency between groups 2 and 4, indicating that the ratio of CD3:CD28 antibodies in the range of 1 to 3:1 has no effect on the activation efficiency. The specific activation efficiency is shown in Table 19.

[0362] Table 19 Activation efficiency

[0363] Group 1 Group 2 Group 3 Group 4 87.28 88.07 87.3 85.17 86.76 88.09 88.44 86.42

[0364] 3) Amplification multiple: Fig.15 As shown in Table 20, the amplification times of groups 2 to 4 were all higher than those of group 1, while there was no significant difference between groups 2 to 4, indicating that the ratio of CD3 to CD28 antibodies in the range of 1 to 3:1 had no effect on the amplification times. The specific amplification times are shown in Table 20.

[0365] Table 20 Amplification times

[0366]

[0367] In summary, Example 5 couples magnetic beads by different ratios of CD3 and CD28 antibodies, and comprehensively analyzes the experimental data of sorting efficiency, activation efficiency, and amplification multiples to find that when the ratio of CD3 to CD28 is 1 to 3:1, all indicators are better.

[0368] Example 6

[0369] 1. Experimental Materials

[0370] Carboxyl magnetic beads (naked beads), MES buffer, CB buffer, blocking buffer, storage buffer, anti-human CD3 monoclonal antibody, anti-human CD28 monoclonal antibody, EDC, NHS,

[0371] 2. Reagent preparation

[0372] The reagents were prepared in the same manner as in Example 1.

[0373] 3. Experimental methods

[0374] Comparison by different coupling methods

[0375] Group 1: Coupling was performed according to patent application publication number CN110568176A “A method for directional coupling of antibodies and magnetic beads”.

[0376] Group 2: Coupling according to the optimized scheme in this article:

[0377] 1) Take out the carboxyl magnetic beads from the 2-8°C refrigerator according to the experimental protocol and mix thoroughly on a vortex shaker for 1 min.

[0378] 2) Place the carboxyl magnetic beads in a biosafety cabinet, mix thoroughly by turning upside down, take out 100 μL of carboxyl magnetic beads, put them into a sterile 1.5 mL Eppendorf tube, add 1 mL of MES buffer to resuspend, and mix thoroughly by turning upside down.

[0379] 3) Place the Eppendorf tube on the magnetic rack, let it stand for 1 min, and discard the supernatant.

[0380] 4) Remove the tube from the magnetic rack, add 1 mL of MES buffer to resuspend, and mix by inverting.

[0381] 5) Repeat steps 3) and 4);

[0382] 6) Place the Eppendorf tube on the magnetic rack, let it stand for 1 min, discard the supernatant, aspirate as much as possible, and resuspend the magnetic beads in 300 μL MES buffer.

[0383] 7) Add 30 μL of 1 mg / mL EDC and shake at room temperature for 1 h.

[0384] 8) Add 1 mL of PBS to resuspend, place the Eppendorf tube on a magnetic rack, let stand for 1 min, and discard the supernatant.

[0385] 9) Remove the tube from the magnetic rack, add 1 mL of PBS to resuspend, mix by inverting, place the Ep tube on the magnetic rack, let it stand for 1 min, and discard the supernatant.

[0386] 10) Repeat step 9) 2 times.

[0387] 11) Resuspend the magnetic beads in 300 μL PBS, add 30 μL 1 mg / mL NHS, and shake at room temperature for 1 hour.

[0388] 12) Add 1 mL PBS to resuspend, place the Eppendorf tube on a magnetic rack, let stand for 1 min, and discard the supernatant.

[0389] 13) Remove the tube from the magnetic rack, add 1 mL of PBS to resuspend, mix by inverting, place the Ep tube on the magnetic rack, let it stand for 1 min, and discard the supernatant.

[0390] 14) Repeat step 13) twice and add 1 mL PBS to resuspend the magnetic beads.

[0391] 15) Remove the Eppendorf tube from the magnetic stand, add 600 μL PBS to resuspend the magnetic beads, and then add 200 μL of 1 mg / mL CD3 and CD28 monoclonal antibody stock solutions.

[0392] 16) Mix by inverting and shaking at 2-8℃ for 2.5h.

[0393] 17) Place the Eppendorf tube on the magnetic rack, let it stand for 1 minute and discard the supernatant.

[0394] 18) Remove the tube from the magnetic stand, add 1 mL of PBS to resuspend, and invert to mix.

[0395] 19) Repeat steps 17) and 18);

[0396] 20) Place the Eppendorf tube on the magnetic rack, let it stand for 1 minute, discard the supernatant, aspirate as much as possible, and resuspend the magnetic beads in 1 mL of blocking buffer.

[0397] 21) Mix by shaking at 2-8℃ for 1 hour.

[0398] 22) Place the Eppendorf tube on the magnetic rack, let it stand for 1 min, and discard the supernatant.

[0399] 23) Remove the tube from the magnetic rack, add 1 mL of storage buffer to resuspend, and invert to mix.

[0400] 24) Repeat steps 22) and 23) twice;

[0401] 25) Place the Eppendorf tube on the magnetic rack, let it stand for 1 minute, discard the supernatant, aspirate as much as possible, and resuspend the magnetic beads in 200 μL storage buffer.

[0402] 26) If you do not proceed to the next step, wrap the tube with sealing film and store it at 4℃.

[0403] (2) Magnetic bead activity test

[0404] The steps are the same as those of the magnetic bead activity test in Example 1.

[0405] 4. Experimental results

[0406] 1) Sorting efficiency

[0407] like Fig.16 As shown in Table 21, the sorting efficiency of Group 2 is higher than that of Group 1, indicating that the optimized coupling method in this paper can improve the sorting efficiency of CD3 / CD28 sorting activated magnetic beads. The specific sorting efficiency is shown in Table 21.

[0408] Table 21 Sorting efficiency

[0409] Group 1 Group 2 48.27 68.83 53.34 64.53

[0410] 2) Activation efficiency

[0411] like Fig.17 As shown in Table 22, there is no significant difference in activation efficiency between Group 1 and Group 2, indicating that different coupling processes have no effect on the activation efficiency of cells. The specific activation efficiency is shown in Table 22.

[0412] Table 22 Activation efficiency

[0413] Group 1 Group 2 88.45 89.58 83.58 85.83

[0414] 3) Amplification multiple

[0415] like Fig.18 As shown in Table 23, the expansion multiples of group 2 were higher than those of group 1, indicating that the optimized coupling method in this paper can increase the expansion multiples of T cells. The specific expansion multiples are shown in Table 23.

[0416] Table 23 Amplification times

[0417]

[0418] In summary, Example 6 compares the conventional and optimized magnetic bead-coupled antibody processes, and comprehensively analyzes the sorting efficiency, activation efficiency, and amplification multiple experimental data to find that the optimized coupling process is more suitable for the coupling of CD3 / CD28 antibodies.

Claims

1. A method for coupling magnetic beads, characterized in that: The coupling method comprises: 1) Mix the carboxyl magnetic beads thoroughly, add MES buffer with a pH value of 5.5-6.5 to resuspend, mix well, let stand on the magnetic rack, discard the supernatant, and repeat step 1) multiple times; 2) Add MES buffer with the same pH value as step 1) to resuspend, add EDC, and mix for 1 h; 3) Add PBS to resuspend, mix well, let stand on a magnetic rack, discard the supernatant, and repeat step 3) several times; 4) Add PBS to resuspend the magnetic beads, add NHS, and mix for 1 h; 5) Add PBS to resuspend, mix well, let stand on a magnetic rack, discard the supernatant, and repeat step 5) several times; 6) Add PBS to resuspend the magnetic beads, add CD3 and CD28 monoclonal antibody stock solutions, mix for 2.5 hours, let stand on the magnetic rack and discard the supernatant; 7) Add PBS to resuspend, mix well, let stand on a magnetic rack, discard the supernatant, and repeat step 7) several times; 8) Add blocking buffer to resuspend the magnetic beads and mix for 1 h; 9) After standing on the magnetic stand, discard the supernatant; 10) Add storage buffer to resuspend, mix well, let stand on a magnetic rack, discard the supernatant, and repeat step 10) multiple times; 11) Add storage buffer to resuspend the magnetic beads to obtain coupled magnetic beads; In step 6), the ratio of CD3 and CD28 to the magnetic beads added in step 1) is 200-300 μL: 200-100 μL: 100 μL; The concentration of CD3 in step 6) is 1-5 mg / mL; The concentration of CD28 in step 6) is 1-5 mg / mL.

2. The coupling method according to claim 1, characterized in that In step 1), the ratio of the MES buffer used for resuspension to the added magnetic beads is 1 mL:100 μL.

3. The coupling method according to claim 1, characterized in that In the step 1), after adding the MES buffer, the mixing method is to invert the mixture.

4. The coupling method according to claim 1, characterized in that The ratio of MES buffer in step 2) to the magnetic beads added in step 1) is 300 μL:100 μL.

5. The coupling method according to claim 1, characterized in that The ratio of EDC in step 2) to the magnetic beads added in step 1) is 10-50 μL:100 μL.

6. The coupling method according to claim 1, characterized in that The mixing method in step 2) is shaking mixing at room temperature.

7. The coupling method according to claim 1, characterized in that The ratio of PBS in step 3) to the magnetic beads added in step 1) is 1 mL:100 μL.

8. The coupling method according to claim 1, characterized in that The mixing method in step 3) is to mix by turning the mixture upside down.

9. The coupling method according to claim 1, characterized in that The ratio of PBS in step 4) to the magnetic beads added in step 1) is 300 μL:100 μL.

10. The coupling method according to claim 1, characterized in that The ratio of NHS in step 4) to the magnetic beads added in step 1) is 10-100 μL:100 μL.

11. The coupling method according to claim 1, characterized in that The mixing method in step 4) is shaking mixing at room temperature.

12. The coupling method according to claim 1, characterized in that The ratio of PBS in step 5) to the magnetic beads added in step 1) is 1 mL:100 μL.

13. The coupling method according to claim 1, characterized in that The mixing method in step 5) is to mix by turning the mixture upside down.

14. The coupling method according to claim 1, characterized in that The ratio of PBS in step 6) to the magnetic beads added in step 1) is 600 μL:100 μL.

15. The coupling method according to claim 1, characterized in that The mixing method in step 6) is shaking mixing at 2-8°C.

16. The coupling method according to claim 1, characterized in that The ratio of PBS in step 7) to the magnetic beads added in step 1) is 1 mL:100 μL.

17. The coupling method according to claim 1, characterized in that The mixing method in step 7) is to mix by turning the mixture upside down.

18. The coupling method according to claim 1, characterized in that The ratio of the blocking buffer in step 8) to the magnetic beads added in step 1) is 1 mL:100 μL.

19. The coupling method according to claim 1, characterized in that The mixing method in step 8) is shaking mixing at 2-8°C.

20. The coupling method according to claim 1, characterized in that The ratio of the storage buffer in step 10) to the magnetic beads added in step 1) is 1 mL:100 μL.

21. The coupling method according to claim 1, characterized in that The mixing method in step 10) is to mix by turning the mixture upside down.

22. The coupling method according to claim 1, characterized in that The ratio of the storage buffer in step 11) to the magnetic beads added in step 1) is 200 μL:200 μL.

23. The coupling method according to claim 1, characterized in that The MES buffer composition is MES: water for injection = 1.59 g: 50 mL, and the pH value is adjusted to 4.5-6.

5.

24. The coupling method according to claim 1, characterized in that The PBS composition is NaCl: KCl: Na2HPO4: KH2PO4: water for injection = 8 g: 0.2 g: 1.44 g: 0.24 g: 1 L.

25. The coupling method according to claim 1, characterized in that The concentration of EDC in step 2) is 1 mg / mL, and the components of 1 mg / mL EDC are EDC: MES = 0.01 g: 10 mL. The EDC needs to be prepared before use.

26. The coupling method according to claim 1, characterized in that The concentration of NHS in step 4) is 1 mg / mL, and the composition of the 1 mg / mL NHS is NHS: PBS = 0.01 g: 10 mL. The NHS needs to be prepared before use.

27. The coupling method according to claim 1, characterized in that The blocking buffer comprises 20 mM PBS and 1% BSA.

28. The coupling method according to claim 1, characterized in that The components of the storage buffer are 20 mM PBS and 5% BSA.